Introduction {#s1}
============

Pandemic influenza A causes appreciable morbidity, mortality and disruption to normal life.^[@DKS418C1],[@DKS418C2]^ Chemoprophylaxis of key societal workers, such as healthcare professionals and firemen/women, needs to be effective and well tolerated.

The adamantanes, amantadine and rimantadine, are unsuitable for prophylaxis because of widespread resistance by the 2009 pandemic (pdm09) A/H1N1 and seasonal A/H3N2 viruses and most A/H5N1 clades^[@DKS418C3]--[@DKS418C5]^ and poor prophylactic efficacy.^[@DKS418C6],[@DKS418C7]^

The neuraminidase inhibitors oseltamivir and zanamivir are generally effective for preventing laboratory-confirmed influenza when used for limited time periods as primary^[@DKS418C8]--[@DKS418C11]^ or post-exposure^[@DKS418C12]--[@DKS418C14]^ prophylaxis in healthy adults,^[@DKS418C8]^ individuals with comorbidities,^[@DKS418C9]^ healthy soldiers^[@DKS418C12]^ and households.^[@DKS418C13],[@DKS418C14]^ Systematic reviews are in accordance with the findings of individual studies.^[@DKS418C7],[@DKS418C15],[@DKS418C16]^

Oseltamivir resistance is uncommon in pdm09 A/H1N1,^[@DKS418C17]^ A/H5N1^[@DKS418C18]^ and A/H3N2^[@DKS418C19]^ and common in seasonal A/H1N1,^[@DKS418C20]--[@DKS418C22]^ but circulation of this virus has been replaced by pdm09 A/H1N1.^[@DKS418C23]^ Resistance to oseltamivir has developed during prophylaxis of pdm09 A/H1N1^[@DKS418C24],[@DKS418C25]^ and during use as treatment for A/H5N1.^[@DKS418C26]^ Molecular markers conferring zanamivir resistance are reported rarely in pdm09 A/H1N1, seasonal A/H1N1 and A/H3N2,^[@DKS418C27],[@DKS418C28]^ but their clinical significance is unclear.

Oseltamivir as prophylaxis is generally well tolerated, including in younger children.^[@DKS418C29]^ Reported adverse event (AE) rates over 6 weeks include headache (∼20%), nausea (∼8%), fatigue (∼8%), diarrhoea (3%) and vomiting (∼2%).^[@DKS418C30]^ In one large prophylaxis trial of two oseltamivir doses, rates of stopping oseltamivir due to AEs/intercurrent illnesses were similar to placebo (≤1.9%), but rates of nausea (12% and ∼14% versus ∼7%) and vomiting (∼2.6% versus 0.8%) were significantly higher in the oseltamivir groups.^[@DKS418C8]^ Poor tolerability was one important reason for reduced compliance (77% and 85%) with oseltamivir prophylaxis for 10 days in British school children.^[@DKS418C31],[@DKS418C32]^ Four of 42 health workers discontinued oseltamivir prophylaxis for a median time on oseltamivir of 3 months. Breakthrough, laboratory-confirmed influenza was observed in 24% and 17% of oseltamivir and influenza vaccine recipients, respectively (not significantly different).^[@DKS418C33]^

Bizarre behaviour, acute confusion, delusions/perceptual disturbances, self-harm and accidental deaths have been reported contemporaneously with oseltamivir treatment, mostly in Japanese adolescents.^[@DKS418C34],[@DKS418C35]^ These AEs were very rare (99/1 000 000 and 28/1 000 000 in Japanese children and adults, respectively), and occurred at similar rates between oseltamivir-treated and untreated patients.^[@DKS418C36]^ Retrospective studies suggested oseltamivir was protective against acute psychiatric AEs.^[@DKS418C37],[@DKS418C38]^

Zanamivir, delivered as a powder for oral inhalation by a Diskhaler, is also well tolerated. As prophylaxis, clinical AE rates over 28 days, e.g. headache (24%), throat discomfort (19%), cough (17%), and nausea and vomiting (2%), are very similar to those of placebo.^[@DKS418C39]^ Serious AE (SAE) rates are low (\<1%), similar to placebo, and have usually been related to influenza or underlying illnesses.^[@DKS418C40]^ Similar findings have been documented in asthma and chronic obstructive pulmonary disease (COPD) sufferers and the elderly (≥65 years).^[@DKS418C41]^ Inhaled zanamivir has been associated rarely with wheezing, including in non-asthmatics, shortness of breath, anaphylaxis, urticaria, and facial and oropharyngeal oedema.

Oseltamivir and zanamivir are registered as prophylaxis for up to 42 and 28 days, respectively, insufficiently long to cover pandemic influenza. Herein we report a 16 week prophylaxis study.

Materials and methods {#s2}
=====================

Trial design {#s2a}
------------

The aim of this randomized, parallel group, double-blind trial was to assess the tolerability and safety of daily oseltamivir relative to oseltamivir placebo, and daily inhaled zanamivir relative to zanamivir placebo, as primary prophylaxis over 16 weeks.

Participants {#s2b}
------------

Subjects were health professionals who had to be literate, healthy males or females age \>20 and \<65 years, who provided written informed consent, and, if appropriate, agreed to use birth control.

Exclusion criteria were any of the following: (1) pregnant, trying to get pregnant or breast feeding; (2) asthma or COPD within the last 5 years requiring treatment; (3) any other chronic or acute disease requiring treatment; (4) study drug allergy; (5) haemoglobin \<11 g/dL, neutropenia \<1000/μL, platelet count \<100 000/μL, creatinine clearance \<30 mL/min (Cockcroft--Gault formula), aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥1.5× the upper limit of normal (ULN); (6) forced vital capacity (FVC) \<80% of the predicted value for age and sex; (7) forced expiratory volume in 1 s (FEV~1~)/FVC \<75% (age \<50 years) or \<70% (≥50 years); (8) acutely abnormal chest X-ray; (9) ECG abnormality requiring immediate treatment/investigation; (10) participation in an investigational drug study within the previous 60 days; (11) received a live-attenuated influenza vaccine or any anti-influenza drug in the last 14 days (influenza vaccine was not allowed in the study); (12) alcohol or substance abuse; and (13) any psychiatric disease requiring treatment within the last 12 months or attempted suicide within last 5 years or a Hospital Anxiety and Depression Scale (HADS) score ≥8.

The study took place at Siriraj Hospital and the Hospital for Tropical Diseases (HTD), Bangkok, Thailand. Ethical approval was obtained from Siriraj Hospital, the Faculty of Tropical Medicine, and the Oxford University Tropical Ethics Committee. The trial is registered at ClinicalTrials.gov (no. NCT00980109).

Interventions {#s2c}
-------------

Doses were oseltamivir/placebo 75 mg once/day or zanamivir/placebo two inhalations once/day (5 mg/inhalation) for 16 weeks (112 days). Dosing was supervised during the working week by the study team and self-administered during weekends and holidays; a diary was used to record drug intake and symptoms. Subjects were instructed to replace missed doses only within 12 h. If ≥12 h had elapsed, this was considered a missed dose.

Outcomes {#s2d}
--------

The primary endpoint was subjects withdrawing from the study because of serious or grade ≥2 AEs that were possibly, probably or definitely drug related.

The secondary endpoints included (1) the proportions of subjects who withdrew from the study because of SAEs or AEs graded ≥2 unlikely or not related to study drug/placebo; with any SAE or AE, irrespective of drug relationship or with any psychiatric AE; and (2) the total number of documented AEs at each follow-up visit. AEs were graded using the 2004 Division of AIDS Toxicity Table.^[@DKS418C42]^

Other endpoints included (1) respiratory function and (2) ECG changes over time, (3) oseltamivir and oseltamivir carboxylate (OC) pharmacokinetic profiles and their relationships with drug-related AEs, (4) development of influenza-like illness (ILI) and laboratory-confirmed influenza, and (5) susceptibility of isolated viruses to oseltamivir, zanamivir and adamantanes (genotypic and phenotypic assays).

Sample size {#s2e}
-----------

The sample size was based on placebo AE rates of 1%, 5%, 10%, 15%, 20% and 25%. For a power of 90% and two-sided α of 0.05, sample sizes of 100 (active arms) and 50 (placebo arms) would be able to detect corresponding differences in absolute AE rates of 14%, 19%, 22%, 25%, 26% and 27% (e.g. 1% versus 15%, etc.). With 100 subjects there was a 90% chance of observing a drug-related AE if its incidence was 2.3%. We recruited 130 (active arms) and 65 subjects (placebo arms), allowing for follow-up losses.

Randomization, allocation and blinding {#s2f}
--------------------------------------

Randomization was computer generated using a randomly permuted, variable block design, stratified by site, in a 2 active : 1 placebo ratio. Study codes and sequentially numbered, sealed opaque envelopes containing the drug/placebo regimen were kept securely at each site.

Study drugs/placebos sufficient for the study duration were packaged into kits. After enrolment, the site pharmacists opened the envelopes and assigned the appropriate drug kits. The randomization number of the assigned drug kit was the subject study number and was used on the case record forms.

Active and placebo oseltamivir capsules (Tamiflu®, Roche, Switzerland) and zanamivir/placebo (zanamivir, zanamivir placebo) Rotadisks and Diskhalers \[Relenza® Rotadisk, GlaxoSmithKline (GSK), USA\] were identical in appearance and supplied by their manufacturers (zanamivir placebo contained the same lactose inhalation powder).

Study assessments {#s2g}
-----------------

Potential subjects were screened by history, questionnaires, clinical examination, haematology, biochemistry, 12-lead ECGs, lung function and urine pregnancy tests. On study, assessments were conducted at different times over 16 weeks. Pregnancy tests were repeated at week 4, 8, 12 and 16. Women found to be pregnant were withdrawn from further study drug/placebo.

Subjects were asked how they were each time they received the study drug/placebo and grade 2 and above AEs were noted. At week 0 (baseline), 4, 8, 12 and 16, team members also administered a symptom questionnaire of 19 symptoms \[cough, sore throat, difficulty breathing, wheeze, appetite, nausea, vomiting, abdominal pain, diarrhoea (\>3 liquid stools/day), constipation, skin rash, itching, muscle pains, joint pains, headache, dizziness, visual hallucinations, auditory hallucinations, fatigue\] and 'others.'

HADS was administered at week 0, 1, 2, 4, 8, 12 and 16 or if subjects withdrew from the study. Scores of 0--7 are normal, 8--10 borderline and ≥11 indicate anxiety or depression. The Thai Delirium Rating Scale (TDRS) was administered if indicated; a score \>10 suggests acute confusion.

Blood sampling {#s2h}
--------------

Haematology and biochemistry were performed at week 0, 1, 2, 4, 8, 12 and 16. Samples for oseltamivir and OC drug measurements were taken at week 2 and 16 (trough concentrations), week 1, 4, 8 and 12 \[peak concentrations (2--4 h post-dose)\] and randomly for SAEs or grade 3 or 4 AEs possibly, probably or definitely related to oseltamivir.

Lung function and ECG {#s2i}
---------------------

The FVC, FEV~1~, FEV~1~/FVC ratio and forced expiratory flow between 25% and 75% of the FVC (FEF25--75%) were recorded at week 0, 1, 4/5, 8/9 and 11/12 \[Sensormedics Corporation, California, USA (Siriraj Hospital) and Micro Medical Ltd, UK (HTD)\]. Twelve-lead ECGs were performed at week 0, 1, 8 and 16 \[Nikon Kohden Corp., Japan (HTD)\] and read by experienced team physicians assisted by cardiologists. We used the Fridericia corrected QT interval: QTcF = QT/^3^√ (RR interval).

ILI and virological diagnostics {#s2j}
-------------------------------

Subjects with an ILI (oral temperature \>37.8°C) and cough and/or sore throat/rhinorrhoea were clinically evaluated and had nasopharyngeal aspirate and throat swab samples taken for real-time reverse transcriptase PCR (RT--PCR) for seasonal influenza A/H1N1, A/H3N2, B and pdm09 A/H1N1;^[@DKS418C43]^ acute and 14 day convalescent influenza serology (haemagglutination inhibition and microneutralization)^[@DKS418C44]^ and oseltamivir/OC concentrations.

Viral culture was performed on Madin-Darby Canine Kidney (MDCK) cells ATCC CCL-34.^[@DKS418C44]^ If influenza viruses were isolated, they were further tested by sequencing of haemagglutinin and neuraminidase genes for mutational positions of drug resistance, phenotypic testing (in-house viral nucleoprotein reduction assay against oseltamivir and zanamivir using MDCK cells) and neuraminidase inhibition assay to measure 50% inhibitory concentration (IC~50~).^[@DKS418C45]^ If subjects had RT--PCR-proven influenza, they were withdrawn from the study and treated as clinically indicated.

Statistical methods {#s2k}
-------------------

Data management, undertaken by Biophics, Thailand, used the Datafax system. All analyses \[Stata v11 (Stata Corporation, College Station, TX, USA)\] were based on subjects who received at least one dose of study drug/placebo: (1) χ^2^ or Fisher\'s exact test (proportional data); (2) comparisons between continuous variables at a given time and baseline were assessed by paired *t*-test or Wilcoxon signed-rank test; (3) changes in laboratory, lung function parameters and QTcF intervals over time by random effects regression model to account for multiple measurements per subject; and (4) linear changes in these parameters over time were examined and tested using likelihood ratio statistics.

Results {#s3}
=======

Patient disposition and general characteristics {#s3a}
-----------------------------------------------

Of the 451 screened subjects, 390 \[285 (73.1%) females\] were enrolled; 25 (6.4%) did not complete the study (Figure [1](#DKS418F1){ref-type="fig"}): 9 (oseltamivir), 3 (oseltamivir placebo), 10 (zanamivir) and 3 (zanamivir placebo). Five physician withdrawals were due to the late discovery of four wrongly randomized subjects \[abnormal lung function (3), received an investigational drug (1)\] and one subject who was not compliant with taking the study drug/placebo. Most volunteers were free of symptoms, signs and abnormal test results (Table [1](#DKS418TB1){ref-type="table"}). The study started in October 2009; the last patient finished follow-up in April 2010. Table 1.Baseline characteristics of enrolled subjectsParameterOseltamivir (*n* = 129)Oseltamivir placebo (*n* = 65)Zanamivir (*n* = 131)Zanamivir placebo (*n* = 65)Age32 (20--55)30 (20--57)31 (20--61)30 (21--52)Female94 (72.9)45 (69.2)99 (75.6)47 (72.3)Male35 (27.1)20 (30.8)32 (24.4)18 (27.7)No symptoms reported general symptoms129 (100)65 (100)129 (98.5)64 (98.5) respiratory symptoms120 (93.0)62 (95.4)122 (93.1)63 (96.9) gastrointestinal symptoms126 (97.7)60 (92.3)122 (93.1)61 (93.8) skin symptoms127 (98.5)64 (98.5)130 (99.2)65 (100) musculoskeletal symptoms115 (89.1)57 (87.7)121 (92.4)58 (89.2) neurological symptoms126 (97.7)62 (95.4)126 (96.2)64 (98.5) psychiatric symptoms129 (100)65 (100)131 (100)65 (100)Physical examination temperature (°C)36.4 (36.0--37.3)36.4 (35.9--37.2)36.5 (36.0--37.3)36.5 (36.0--37.3) pulse (beats/min)76 (60--104)75 (50--99)75 (50--98)76 (58--98) systolic BP (mmHg)112 (95--147)120 (90--142)111 (90--144)110 (89--141) diastolic BP (mmHg)70 (50--106)70 (48--91)70 (50--97)70 (50--96) respiratory rate/minute18 (16--20)18 (16--20)18 (16--20)20 (16--20) GA: normal124 (96.1)64 (98.5)126 (96.2)60 (92.3) ENT: normal125 (96.9)64 (98.5)129 (98.5)65 (100) heart : normal129 (100)65 (100)131 (100)65 (100) lungs: normal129 (100)65 (100)131 (100)65 (100) abdomen: normal128 (99.2)64 (98.5)129 (98.5)61 (93.9) neurological: normal129 (100)65 (100)131 (100)65 (100) skin: normal127 (98.5)63 (96.9)126 (96.2)62 (95.4)Pulmonary function tests FEV~1~/FVC ratio: normal128 (99.2)63 (96.9)128 (97.7)63 (96.9) grade 11 (0.8)2 (3.1)3 (2.3)2 (3.1) mean FEV~1~/FVC^a^87.1 (5.1)86.4 (5.1)86.4 (5.6)86.2 (5.5)HADS anxiety score 0--7129 (100)65 (100)131 (100)65 (100) depression score 0--7129 (100)65 (100)131 (100)65 (100)Haematology haemoglobin (g/dL)12.8 (11--16.3)13 (11.1--15.5)12.7 (11--120)13.1 (11.3--16.1) platelet count (10^3^/μL)261 (141--483)249 (134--390)248 (135--434)251 (135--370) white blood cell (10^3^/μL)6.8 (3.4--10.6)7.2 (3.9--10.5)6.6 (3.9--13.0)6.7 (3.5--10.7)Biochemistry glucose (mg/dL)91 (75--118)90 (75--124)91 (75--129)91 (77--108) creatinine (mg/dL)0.7 (0.5--1.18)0.75 (0.5--1.27)0.74 (0.49--1.37)0.75 (0.4--1.13) total bilirubin (mg/dL)0.48 (0.16--1.44)0.52 (0.18--1.78)0.49 (0.04--1.62)0.49 (0.09--0.95) AST (IU/L)20 (11--44)19 (14--45)19 (8--40)20 (12--45) ALT (IU/L)16 (5--58)16 (9--50)15 (6--51)16 (7--57) sodium (mmol/L)140 (136--144)140 (136--146)140 (135--145)140 (136--147) potassium (mmol/L)4.1 (3.49--5.3)4.2 (3.39--5.15)4.1 (3.4--4.9)4.14 (3.4--5.34) CPK (IU/L)104 (44--800)108 (7.9--1,015)100 (32--504)112 (51--335)[^2][^3][^4] Figure 1.Trial profile.

Compliance {#s3b}
----------

A total of 12 741 oseltamivir/placebo tablets and 12 879 zanamivir/placebo inhalations were supervised; self-administered treatments were 8262 and 8189, respectively. Fully compliant subjects were similar (*P* = 0.5): 120/129 (93%, oseltamivir), 62/65 (95.4%, oseltamivir placebo), 118/131 (90.1%, zanamivir) and 62/65 (95.4%, zanamivir placebo); proportions taking ≥90 doses were 93.8%, 96.9%, 93.1% and 95.4%, respectively.

Outcomes {#s3c}
--------

A total of 102 AEs, graded ≥2, were reported by or detected in 69/390 (17.7%) subjects (Table [2](#DKS418TB2){ref-type="table"}): oseltamivir, 29 AEs in 23/129 (17.8%) subjects; oseltamivir placebo, 25 in 15/65 (23.1%) subjects; zanamivir, 32 in 23/131 (17.6%) subjects; zanamivir placebo, 16 in 8/65 (12.3%) subjects (*P* = 0.459 in a four-arm comparison). All AEs, except one (see below), and all eight SAEs were classified by study physicians as unrelated or unlikely related to the study drugs. Table 2.Summary of the 102 reported and detected grade ≥2 clinical and laboratory AEs, classified by the System Organ ClassificationOseltamivir (*n* = 129)Oseltamivir placebo (*n* = 65)Zanamivir (*n* = 131)Zanamivir placebo (*n* = 65)Number of subjects with at least one AE23 (17.8%)15 (23.1%)23 (17.6%)8 (12.3%)Number of AEs (total)29253216Blood and lymphatic system disorders (total)1001 thrombocytopenia1 (3.4)^a^001 (6.3)Cardiac disorders (total)1000 tachycardia1 (3.4)000Gastrointestinal disorders (total)6552 abdominal pain01 (4.0)00 diarrhoea01 (4.0)02 (12.5) dyspepsia001 (3.1)0 enteritis01 (4.0)00 food poisoning01 (4.0)00 gastritis1 (3.4)02 (6.3)^b^0 gastroenteritis3 (10.3)02 (6.3)0 nausea01 (4.0)00 vomiting2 (6.9)000General disorders and administration site conditions (total)0220 influenza-like illness01 (4.0)2 (6.3)0 pyrexia01 (4.0)00Infections and infestations (total)5674 adenoviral conjunctivitis1 (3.4)000 conjunctivitis viral1 (3.4)000 dengue fever002 (6.3)0 hordeolum01 (4.0)00 otitis media acute001 (3.1)0 pharyngitis2 (6.9)000 rhinitis01 (4.0)00 skin infection001 (3.1)0 upper respiratory tract infection02 (8.0)1 (3.1)3 (18.8) urinary tract infection1 (3.4)000 varicella01 (4.0)00 viral infection01 (4.0)00 viral pharyngitis002 (6.3)0 viral upper respiratory tract infection0001 (6.3)Injury, poisoning and procedural complications (total)2270 fall002 (6.3)0 head injury001 (3.1)0 joint injury01 (4.0)00 joint sprain01 (4.0)00 laceration003 (9.4)0 wound2 (6.9)000 wrist fracture001 (3.1)0Investigations (total)7654 ALT increased1 (3.5)1 (4.0)2 (6.3)0 AST increased02 (8.0)1 (3.1)1 (6.3) bilirubin increased3 (10.3)1 (4.0)2 (6.3)2 (12.5) CPK increased1 (3.5)2 (4.0)01 (6.3) pulmonary function test abnormal2 (6.9)000Metabolism and nutrition disorders (total)2030 dyslipidaemia001 (3.1)0 hyperglycaemia2 (6.9)02 (3.1)0Musculoskeletal and connective tissue disorders (total)1120 back pain01 (4.0)1 (3.1)0 myalgia1 (3.4)01 (3.1)0Nervous system disorders (total)2003 headache1 (3.4)001 (6.3) tension headache0002 (12.5) vertigo1 (3.4)000Pregnancy, puerperium and perinatal conditions (total)1110 abortion complete001 (3.1)0 abortion complete complicated01 (4.0)00 blighted ovum1 (3.4)000Psychiatric disorders (total)0200 anxiety01 (4.0)00 stress01 (4.0)00Renal and urinary disorders (total)0001 calculus urinary0001 (6.3)Vascular disorders (total)1000 hypertension1 (3.4)000[^5][^6]

Eighty-five (83.3%) AEs were grade 2. Twelve of the 17 grade 3--4 AEs required treatment: urinary calculus, dengue fever (*n* = 2), fall (*n* = 2), gastritis, head injury, joint injury, joint sprain, acute otitis media, urinary tract infection and a wound infection. The most frequently reported grade 2--4 AEs (Table [2](#DKS418TB2){ref-type="table"}) were coincident infections (*n* = 22) and fevers (*n* = 4) for frequencies of 25.5% (26/102 AEs) and 5.9% (23/390 subjects), abnormal biochemistry results \[*n* = 25, 24.5% and 5.4% (21/390)\] and gastrointestinal (GI) symptoms \[*n* = 18, 17.6% and 3.8% (15/390)\]. There were no significant differences (*P* = 0.2--1.0) in clinical and laboratory AE rates between oseltamivir versus oseltamivir placebo and zanamivir versus zanamivir placebo. There were eight SAEs; all were due to intercurrent illnesses (Table [3](#DKS418TB3){ref-type="table"}). Table 3.Summary of SAEsOseltamivir (*n* = 129)Oseltamivir placebo (*n* = 65)Zanamivir (*n* = 131)Zanamivir placebo (*n* = 65)Number (%) of SAEs2 (1.6)2 (3.1)4 (3.1)0 (0)Gastrointestinal disorders gastritis0010 infections and infestations otitis media acute0010 urinary tract infection1000Injury, poisoning and procedural complications fall0010 joint injury0100Pregnancy, puerperium and perinatal conditions abortion complete0010 abortion complete complicated0100 blighted ovum1000

One oseltamivir/placebo recipient was withdrawn from the study because of an increase in liver enzymes that, at the time, was considered probably drug related. This recipient had baseline AST and ALT values of 45 IU/L. After ∼8 weeks of oseltamivir/placebo she developed a grade 2, asymptomatic increase in AST and ALT of 151 and 142 IU/L, respectively. Hepatitis A, B and C serologies were negative; a liver ultrasound showed only marked fatty liver infiltration. Her code revealed she was an oseltamivir placebo recipient. She probably had non-alcoholic hepatic steatosis.

Twenty-one subjects had abnormal laboratory values graded ≥2; 16 returned to normal by study end and 5 were reported at the last follow-up. ALT, AST and total bilirubin values ranged from 101 to 245, 106 to 165 IU/L and 1.61 to 2.35 mg/dL, respectively. Creatine phosphokinase (CPK) values in three subjects were 948, 2692 and 951 IU/L; all resolved within 1 week, but in the subject whose CPK was 951 IU/L, the CPK rose again to 4726 IU/L at the last follow-up. No laboratory AE was related to either oseltamivir or zanamivir.

Symptom trends {#s3d}
--------------

Trends in the symptoms reported by the questionnaire are shown in Figures [2](#DKS418F2){ref-type="fig"}[](#DKS418F3){ref-type="fig"}[](#DKS418F4){ref-type="fig"}--[5](#DKS418F5){ref-type="fig"}. Most symptoms were grade 1; only five patients reported grade 2 symptoms. Changes in symptom frequencies between arms were not significantly different except for cough. At week 4, mild (grade 1) cough was significantly (*P* = 0.037) higher in the zanamivir arm \[10.3% (13/126)\] versus the zanamivir placebo arm \[1.6% (1/63)\] and significantly (*P* = 0.045) higher in the oseltamivir placebo arm \[8.1% (5/62)\] versus the oseltamivir arm \[1.7% (2/121)\] at week 16. Wheezing was not reported by any subject at any time. Figure 2.Trends in respiratory symptoms by study week elicited by questionnaire for oseltamivir (OS)/placebo (OSp) and zanamivir (ZAN)/placebo (ZANp), expressed as subject proportions. Figure 3.Trends in gastrointestinal symptoms by study week elicited by questionnaire for oseltamivir (OS)/placebo (OSp) and zanamivir (ZAN)/placebo (ZANp), expressed as subject proportions. Figure 4.Trends in musculoskeletal symptoms by study week elicited by questionnaire for oseltamivir (OS)/placebo (OSp) and zanamivir (ZAN)/placebo (ZANp), expressed as subject proportions. Figure 5.Trends in neurological symptoms by study week elicited by questionnaire for oseltamivir (OS)/placebo (OSp) and zanamivir (ZAN)/placebo (ZANp), expressed as subject proportions.

HADS and TDRS scores {#s3e}
--------------------

Most subjects had HADS scores \<8 during the study. No subject had a score ≥11. Three \[9 (*n* = 2)\] and four \[9 (*n* = 1)\] subjects recorded scores of 8 or 9 for anxiety and depression, respectively, at least once during the study; one subject had simultaneous anxiety and depression scores of 9. No scores persisted by study end. Anxiety scores were one each for oseltamivir, zanamivir and zanamivir placebo; elevated depression scores were oseltamivir 4/129 versus oseltamivir placebo 0/65 (*P* = 0.30) and zanamivir 1/131 versus zanamivir placebo 1/65 (*P* = 1). No subjects had an acute psychiatric AE.

Lung function and ECGs {#s3f}
----------------------

The mean FEV~1~/FVC ratios over time were very similar in the four arms at baseline and subsequent follow-ups (data not shown). By study end the FEV~1~/FVC ratio for all subjects increased significantly (*P* \< 0.001 versus day 0) by a mean of 1.8% (95% CI 1.3--2.3%) with similar changes between each arm.

No subject had a QTcF ≥500 ms nor an increase from baseline \>25% at any timepoint. Twenty-three subjects had a QTcF increase ≥30 ms from baseline, distributed similarly (*P* = 1) between the arms: 8/129 (6.2%, oseltamivir), 4/65 (6.15%, oseltamivir placebo), 8/131 (6.1%, zanamivir) and 3/65 (4.6%, zanamivir placebo).

Influenza-like illness {#s3g}
----------------------

Six subjects (1.5%) had ILIs: oseltamivir placebo = 2, zanamivir  = 3 and zanamivir placebo = 1. None was RT--PCR confirmed for influenza A or B, so no further virological investigations were done. Two ILI subjects had acute dengue fever and exudative tonsillitis.

Pregnancies {#s3h}
-----------

Eight women became pregnant during the study. The length of exposure to study drugs/placebos at the time the pregnancies were detected varied from 7 to 112 days. Four delivered healthy female babies (oseltamivir exposure 7, 28 and 82 days; zanamivir 16 days), two had spontaneous abortions (zanamivir 84 days; oseltamivir placebo 20 days), one had a blighted ovum (oseltamivir 112 days) and one was lost to follow-up (zanamivir 28 days).

Discussion {#s4}
==========

In this 16 week study, we showed that healthy Thai health professionals tolerated well oral oseltamivir or zanamivir inhalations. No volunteer stopped oseltamivir or zanamivir because of an adverse drug reaction.

Subjects were followed up closely, ensuring high drug adherence and the early detection of AEs. We recorded clinical and laboratory AEs of at least moderate severity, as these were more likely to be clinically important. Accordingly, our AE rates were considerably lower compared with other studies of oseltamivir^[@DKS418C30]^ and zanamivir^[@DKS418C39]^ and were mostly due to intercurrent illnesses, transient increases in biochemistry and GI symptoms. During the study the clinicians judged that one AE was study drug/placebo related but, on analysis, the subject had received oseltamivir placebo; her diagnosis was probably non-alcoholic hepatic steatosis. Mild cough was reported significantly most often in the zanamivir arm at week 4, declining thereafter, and in the oseltamivir placebo group at study end. Both might be chance findings, but we cannot exclude definitively that zanamivir may cause a transient cough when first used.

The changes in lung function in our lung healthy subjects were clinically unremarkable (more analyses will be presented elsewhere). Similarly there were no clinically significant changes in QTcF intervals, consistent with previous work.^[@DKS418C46],[@DKS418C47]^

Our study had limitations. Both drugs were administered following their current regulatory labels. Pregnant women were excluded. This vulnerable group, which suffers high influenza-related mortality, especially in the third trimester,^[@DKS418C48],[@DKS418C49]^ is a target group for vaccination rather than prophylaxis.^[@DKS418C50]^ This has implications for policy regarding pregnant nurses, who understand the risks to health of contracting influenza at work and the unknown risks of chemoprophylaxis as important concerns.^[@DKS418C51]^

Although women of child-bearing age agreed to use contraception to be enrolled, eight (just under 3%) became pregnant; this remains unexplained. There were no congenital abnormalities in the four live births, three and one of whom had been exposed to oseltamivir and zanamivir, respectively. Although these small numbers *per se* tell us little regarding the safety of both drugs, they are useful contributors to a pregnancy register of drug exposure. Limited data suggest oseltamivir exposure in pregnancy may not be associated with adverse outcomes for the mother and foetus.^[@DKS418C52],[@DKS418C53]^ Currently, there is no pregnancy exposure register for zanamivir. More data collection on accidental exposure to both drugs in early pregnancy are needed.

We also excluded subjects with moderate/severe obstructive airways disease because inhaled zanamivir has been associated rarely with increases in airways obstruction, even in individuals without pre-existing airways disease.^[@DKS418C54]^ Although inhaled zanamivir use in asthmatics and COPD sufferers is not an absolute contraindication, it is not recommended; thus, oseltamivir is the preferred choice. These exclusions and others mandated by the protocol (e.g. laboratory abnormalities) limit the generalizability of our findings to predominantly healthy subjects.

The study was not powered to detect rare side effects of either drug, notably acute psychiatric reactions or acute bronchospasm. Although thought initially to be oseltamivir related, the acute psychiatric reactions are probably influenza related,^[@DKS418C36]^ with limited data suggesting a protective effect in oseltamivir-treated influenza patients.^[@DKS418C38]^

We investigated six subjects with symptomatic ILI, but none had influenza. The study period (October 2009--April 2010) occurred between the two peaks of influenza activity, when community influenza transmission was low.^[@DKS418C55]^ However, prophylaxis failure has also been associated with asymptomatic influenza, and we cannot exclude this possibility.^[@DKS418C56]^ This may be important for infection control in the hospital environment and is an area of future research.

To conclude, this study demonstrated good tolerability of supervised oseltamivir and inhaled zanamivir for 16 weeks. Both are options for influenza prophylaxis. Further work on the effectiveness and acceptability of unsupervised, long-term prophylaxis is warranted.
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[^2]: All continuous data are the median (range) unless otherwise stated. Proportional data are number (%).

[^3]: BP, blood pressure; GA, general assessment; ENT, ears nose and throat; FVC, forced vital capacity; FEV~1~, forced expiratory volume in 1 s; HADS, Hospital Anxiety Depression Scale; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CPK, creatine phosphokinase.

[^4]: ^a^Values are the mean (standard deviation).

[^5]: ^a^Value shown is the number with the percentage of the total number of AEs for that arm in parentheses.

[^6]: ^b^One patient complained originally of dyspnea, but on further evaluation was diagnosed with gastritis.
